Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR -Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
James Chih-Hsin YangDae Ho LeeJong-Seok LeeYun FanFilippo de MarinisEiji IwamaTakako InoueJerónimo Rafael Rodríguez-CidLi ZhangCheng-Ta YangEmmanuel de la Mora JimenezJianying ZhouMaurice PérolKi Hyeong LeeDavid VicenteEiki IchiharaGregory J RielyYiwen LuoDiana ChirovskyM Catherine PietanzaNiyati BhagwatiShun LuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.